Valneva：针对寨卡病毒启动了第一阶段试验。 Valneva: Phase 1 trial initiated in the Zika virus.

特种疫苗公司 Valneva SE 宣布启动针对寨卡病毒的第二代佐剂灭活候选疫苗 VLA1601 的一期临床试验。 Valneva SE, a specialty vaccine company, announced the initiation of a Phase 1 clinical trial for its second-generation adjuvanted inactivated vaccine candidate, VLA1601, against the Zika virus. 该试验名为 VLA1601-102，将在美国招募约 150 名 18-49 岁的参与者，以评估疫苗的安全性和免疫原性。 The trial, VLA1601-102, will enroll around 150 participants aged 18-49 in the US to assess the safety and immunogenicity of the vaccine. 目前，尚无针对寨卡病毒的预防性疫苗或有效治疗方法，使其成为公共卫生威胁。 Currently, no preventive vaccines or effective treatments for Zika virus are available, making it a public health threat.